Anti-TNF-refractory colitis after checkpoint inhibitor therapy: Possible role of CMV-mediated immunopathogenesis.

about

Intestinal perforation after nivolumab immunotherapy for a malignant melanoma: a case report.Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

P2860

Q41527735-3F0CB6A1-03CD-4D63-A34B-FDD50FBB3209 Q50205173-47ADBCB3-F0CD-4281-99AB-AC6A8AE59C0A

P2860

Anti-TNF-refractory colitis after checkpoint inhibitor therapy: Possible role of CMV-mediated immunopathogenesis.

Item

http://www.wikidata.org/entity/Q41826015

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Anti-TNF-refractory colitis af ...... V-mediated immunopathogenesis.

@en

type

Item

label

Anti-TNF-refractory colitis af ...... V-mediated immunopathogenesis.

@en

prefLabel

Anti-TNF-refractory colitis af ...... V-mediated immunopathogenesis.

@en

P1476

Anti-TNF-refractory colitis af ...... V-mediated immunopathogenesis.

@en

P2093

Abbas Agaimy

http://www.w3.org/2001/XMLSchema#string

Ansgar J Pommer

http://www.w3.org/2001/XMLSchema#string

Azadeh Tajmir-Riahi

http://www.w3.org/2001/XMLSchema#string

Gerold Schuler

http://www.w3.org/2001/XMLSchema#string

Gheorghe Hundorfean

http://www.w3.org/2001/XMLSchema#string

Irena Angelovska

http://www.w3.org/2001/XMLSchema#string

Jonas Göhl

http://www.w3.org/2001/XMLSchema#string

Katharina Lankes

http://www.w3.org/2001/XMLSchema#string

Lucie Heinzerling

http://www.w3.org/2001/XMLSchema#string

Markus F Neurath

http://www.w3.org/2001/XMLSchema#string

P2860

Nivolumab plus ipilimumab in advanced melanoma.

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Hepatitis C virus reactivation in cancer patients in the era of targeted therapies.

Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells

Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma.

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

P304

e1128611

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/2162402X.2015.1128611

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27471608

http://www.w3.org/2001/XMLSchema#string

P921

TNF inhibitor

P932

4938313

http://www.w3.org/2001/XMLSchema#string

Anti-TNF-refractory colitis after checkpoint inhibitor therapy: Possible role of CMV-mediated immunopathogenesis.

about

P2860

P2860

Anti-TNF-refractory colitis after checkpoint inhibitor therapy: Possible role of CMV-mediated immunopathogenesis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932